Trials / Completed
CompletedNCT00522652
Phase I Trial of PX-478
A Phase 1 Trial of Oral PX-478 (a HIF-1α Inhibitor) in Patients With Advanced Solid Tumors or Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Cascadian Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to determine the safety and biologic activity of PX-478, and to allow for observation of any preliminary evidence of antitumor activity in patients with advanced metastatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PX-478 | Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2007-08-30
- Last updated
- 2018-05-17
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00522652. Inclusion in this directory is not an endorsement.